Literature DB >> 8512760

Plasma concentrations and ocular effects of cyclopentolate after ocular application of three formulations.

K Lahdes1, R Huupponen, T Kaila, D Monti, M F Saettone, L Salminen.   

Abstract

1. Eight volunteers received in randomized order two 30 microliters drops of either 1% w/v cyclopentolate hydrochloride or a corresponding amount of cyclopentolate polygalacturonate in saline or in acetate buffer in one eye. Cyclopentolate concentrations in plasma were measured by a radioreceptor assay. 2. Peak plasma drug concentrations of about 3 ng ml-1 occurred within 30 min after all formulations. Occasionally, a second concentration peak in plasma, probably reflecting drug absorption from the gastrointestinal tract, was seen after 2 h. The mean elimination half-life of cyclopentolate was 111 min when all subjects and formulations were considered together. There were no statistically significant differences between the formulations with respect to the time-course of plasma drug concentration. 3. The maximal mydriatic effect was reached within about 15 min and was maintained for several hours, often being 1/3 of its peak value after 30 h. Similarly, an intense cycloplegic response was achieved within a few minutes, the peak changes in the near-point of vision being 9 to 10 dioptres. The cycloplegic response was more intense after one of the polygalacturonate complexes, especially at later time points.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8512760      PMCID: PMC1381685          DOI: 10.1111/j.1365-2125.1993.tb04173.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  Factors determining the potency of mydriatic drugs in man.

Authors:  S A Smith
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

2.  Adverse systemic reactions of topical cyclopentolate hydrochloride.

Authors:  K J Awan
Journal:  Ann Ophthalmol       Date:  1976-06

3.  Acute psychosis associated with topical cyclopentolate hydrochloride.

Authors:  A K Khurana; B K Ahluwalia; C Rajan; A K Vohra
Journal:  Am J Ophthalmol       Date:  1988-01-15       Impact factor: 5.258

4.  Systemic absorption of ophthalmic cyclopentolate.

Authors:  T Kaila; R Huupponen; L Salminen; E Iisalo
Journal:  Am J Ophthalmol       Date:  1989-05-15       Impact factor: 5.258

5.  Radioreceptor assay for determination of the antimuscarinic drug ipratropium bromide in man.

Authors:  H A Ensinger; D Wahl; V Brantl
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Cyclopentolate (Cyclogyl) toxicity in pediatric patients.

Authors:  E W Adcock
Journal:  J Pediatr       Date:  1971-07       Impact factor: 4.406

7.  Corneal absorption reinforcement of certain mydriatics.

Authors:  E S Wang; E R Hammarlund
Journal:  J Pharm Sci       Date:  1970-11       Impact factor: 3.534

8.  Psychotic reaction in an adult after topical cyclopentolate.

Authors:  Z M Shihab
Journal:  Ophthalmologica       Date:  1980       Impact factor: 3.250

9.  [Acute psychosis caused by poisoning with cyclopentolate].

Authors:  U Kellner; J Esser
Journal:  Klin Monbl Augenheilkd       Date:  1989-06       Impact factor: 0.700

10.  Comparison of conjunctival and corneal surface areas in rabbit and human.

Authors:  M A Watsky; M M Jablonski; H F Edelhauser
Journal:  Curr Eye Res       Date:  1988-05       Impact factor: 2.424

View more
  2 in total

1.  Systemic Absorption of Cyclopentolate and Adverse Events After Retinopathy of Prematurity Exams.

Authors:  Anita Mitchell; Richard W Hall; Stephen W Erickson; Charlotte Yates; Scott Lowery; Howard Hendrickson
Journal:  Curr Eye Res       Date:  2016-05-09       Impact factor: 2.424

2.  Adverse reactions following routine anticholinergic eye drops in a paediatric population: an observational cohort study.

Authors:  Helena M van Minderhout; Maurits V Joosse; Diana C Grootendorst; Nicoline E Schalij-Delfos
Journal:  BMJ Open       Date:  2015-12-23       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.